Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

327.38 +2.96 (+0.91%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

61 62 Next >

These Were the 5 Top-Performing Stocks in the Dow Jones Industrial Average in January 2025 ↗

February 04, 2025

Via The Motley Fool

Topics Stocks

US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday? ↗

February 04, 2025

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.

Via Benzinga

Analyst Expectations For Amgen's Future ↗

January 28, 2025

Via Benzinga

Earnings Scheduled For February 4, 2025 ↗

February 04, 2025

Via Benzinga

Markets React To Softening Trade Tariff Policy ↗

February 04, 2025

Monday’s trading session resulted in slight negative closes across major indexes, but there’s good news here: whereas the Dow finished the trading day -122 points, it was -400 a half hour before this...

Via Talk Markets

Topics Stocks Stocks / Equities

The Dogs Of The Dow 2025 ↗

January 31, 2025

The Dogs of the Dow is an investing strategy well-known to retail and institutional investors.

Via Talk Markets

Topics Stocks Stocks / Equities

Friday's pre-market session: top gainers and losers in the S&P500 index ↗

January 31, 2025

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

Via Chartmill

This Is What Whales Are Betting On Amgen ↗

January 27, 2025

Via Benzinga

These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024 ↗

January 25, 2025

Via The Motley Fool

Topics Stocks

Unpacking the Latest Options Trading Trends in Amgen ↗

January 13, 2025

Via Benzinga

Peering Into Amgen's Recent Short Interest ↗

January 13, 2025

Via Benzinga

Analyst Expectations For Amgen's Future ↗

January 02, 2025

Via Benzinga

Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results ↗

January 24, 2025

The Danish drug giant reported a 22% weight loss over 36 weeks.

Via Investor's Business Daily

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? ↗

January 21, 2025

Via The Motley Fool

Topics Stocks

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation ↗

January 17, 2025

Amgen's Lumakras treatment, combined with Vectibix, is FDA-approved for KRAS G12C-mutated colorectal cancer.

Via Benzinga

2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows ↗

January 16, 2025

Via The Motley Fool

What Lies Ahead In 2025? Slower Growth, More Volatility ↗

January 14, 2025

As we move through 2025, the global economy and financial markets are facing a critical juncture.

Via Talk Markets

Topics Economy Stocks / Equities

Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows. ↗

January 14, 2025

Via The Motley Fool

3 High-Yield Dividend Stocks to Buy in 2025 ↗

January 13, 2025

Via The Motley Fool

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗

January 09, 2025

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Via Benzinga

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

UK Greenlights Amgen's Drug For Aggressive Lung Cancer In Pretreated Patients ↗

January 06, 2025

Amgen's Imdylltra gets MHRA nod for ES-SCLC after two prior therapies, offering new hope for aggressive cancer with limited treatment options.

Via Benzinga

Prediction: These 3 Healthcare Stocks Will Soar in 2025 ↗

January 04, 2025

Via The Motley Fool

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

January 03, 2025

Via The Motley Fool

Topics Stocks

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

January 03, 2025

Via Benzinga

Dissecting Our Discipline ↗

January 02, 2025

All portfolio managers practice a stock-picking discipline in which they make choices.

Via Talk Markets

Topics Stocks / Equities

Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025 ↗

December 31, 2024

In the Dow Jones Industrial Average, 28 of the 30 components pay dividends. With changes to the components in 2024, dividend yield is smaller overall.

Via Benzinga

Topics Stocks

3 Worst Performing Dow Jones Stocks In 2024 ↗

December 29, 2024

The Dow Jones Industrial Average will finish 2024 with a positive return. The index has climbed about 24% this year.

Via Talk Markets

Topics Stocks Stocks / Equities

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

61 62 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Amgen (NQ:AMGN)

All News about Amgen

Starting at $3.75/week.

Subscribe Today